Date
Title
Date
07/12/22
Title
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
Date
07/12/22
Title
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
Date
06/08/22
Title
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
Date
06/01/22
Title
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
Date
05/26/22
Title
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
Date
05/05/22
Title
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Date
04/11/22
Title
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
Date
04/08/22
Title
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
Date
04/07/22
Title
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
Date
04/06/22
Title
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference